Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Mar 2, 2017
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq: KITE) today announced the commencement of an underwritten public offering of 4,750,000 shares of its common stock. In addition, Kite has granted the underwriters of the offering a 30-day option to purchase up to an additional 712,500 shares of its...
Feb 28, 2017
Strong Execution Across Clinical Development, Pipeline, Manufacturing and Pre-Commercial Activities in 2016 On Track to Complete Rolling Biologics License Application to the U.S. Food and Drug Administration for Axicabtagene Ciloleucel by End of First Quarter 2017 ...
Feb 28, 2017
Met Primary Endpoint of Objective Response Rate (p...
Feb 27, 2017
Conference Call and Webcast Scheduled for 6:00 AM PT/9:00 AM ET SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced that it will report fourth quarter and full year 2016 financial results on Tuesday, February 28, 2017, prior to the open of the market. The ...
Jan 10, 2017
Kite to Receive Upfront Payment of $40 Million, Milestone Payments, Profit Share and Sales Royalties Upon Commercialization of Axicabtagene Ciloleucel (approved USAN name for KTE-C19) in China Fosun Pharma to Provide $20 Million in Initial Funding to Support Clinical Development and Ma...
Jan 9, 2017
Upfront and Milestone Payments Total $250 Million Plus Double Digit Sales Royalties Accelerates Development of Axicabtagene Ciloleucel for Aggressive Non-Hodgkin Lymphoma (NHL) in Third-Largest Pharmaceutical Market in the World SANTA MONICA, Ca...
Jan 5, 2017
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced that Ian T. Clark, former Chief Executive Officer, Head of Commercial Operations and member of the Board of Directors for Genentech Inc., a member of the Roche Group, has been appointed to its Board of Directors. Clar...
Jan 4, 2017
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (NASDAQ:KITE) today announced that Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer, will present at the 35th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2017 at 4:30 PM Pacific Time. The event wi...
Jan 3, 2017
Directed Against a Validated TCR Target in Solid Tumors Built on the National Cancer Institute Proof of Concept Work and Optimized to Include Next Generation T-cell Manufacturing Technologies SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharm...
Dec 19, 2016
Kite to Appeal USPTO Declining to Revoke Narrow Patent Against Certain CAR-T Constructs having a Single Specified CD28 Sequence Kite Successfully Defeats 3rd Party Challenge to Kite CAR-T Patent which Covers Methods for Using Modified T cells Containing scFv Binding Elements and Other ...
Dec 13, 2016
Strategic Partnership will Connect Vitruvian's Cloud-Based Software with Kite Pharma's Kite Konnect™ Platform to Enable Commercial-Scale Logistics for T-cell Therapies SANTA MONICA, Calif. and SAN FRANCISCO--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq: KITE) and Vitruvian Networks, Inc...
Dec 12, 2016
Publication Describes Work Pertaining to the Cooperative Research and Development Agreement (CRADA) between the National Institutes of Health (NIH) and Kite Pharma Kite Pharma Has an Exclusive License from NIH to Multiple T Cell Receptor (TCR) Product Candidates Targeting Mutant KRAS t...
Dec 6, 2016
76 Percent of Patients with Diffuse Large B-Cell Lymphoma Achieved Objective Response (p ...
Dec 4, 2016
•First CAR-T Therapy BLA Filing Initiated with the U.S. Food and Drug Administration •Company Expects to Complete BLA Submission by the end of Q1 2017 •United States Adopted Name, or USAN, for KTE-C19 will be axicabtagene ciloleucel ...
Dec 4, 2016
• 100 Percent of Responders Tested Negative for Minimal Residual Disease (MRD) SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE) today announced that 82 percent of patients (9 out of 11) achieved complete remission or complete remission wi...
= add release to Briefcase